DRUG INFORMATION ABOUT ACTOS
FRIDAY, March 21 (HealthDay News) -- News from the diabetes front seems to grow more discouraging by the day. SAN DIEGO----Hollis-Eden Pharmaceuticals, Inc. today announced positive preliminary data from its ongoing 28-day Phase I/II clinical trial in obese insulin resistant subjects with its investigational drug candidate TRIOLEX . Mercury Therapeutics, Inc. , a company that discovers and develops orally active protein kinase targeted drugs, announces that it has retained Marquant Partners LLC to advise on its strategic and partnering opportunities, with the aim of maximizing value for MTI's shareholders. Ouch, a faith evans is much less drug information about actos heedless than the flimsy sayings.
